 DURHAM, NC ACCESSWIRE March 25, 2021 Heat Biologics, Inc. NASDAQ:HTBX, a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today provided financial, clinical and operational updates for the year ended December 31, 2020. Jeff Wolf, Chief Executive Officer of Heat, commented, We made tremendous progress on our clinical programs in 2020. 